Research news · menopause care
Hot flashes treatment guidelines: what the American College of Physicians recommended
New hot flashes treatment guidelines from the American College of Physicians (ACP), published Oct 6, 2026 in Annals of Internal Medicine, rank medicines for hot flashes and night sweats (vasomotor symptoms). A Nov 12, 2026 U.S. Medicine report summarized the ladder: hormone therapy first, then certain other medicines if hormones are not suitable. This page is a plain-language summary of that reporting. It is not personal treatment advice, and an antiperspirant does not treat hot flashes.
Hot flashes treatment guidelines at a glance
- ACP says vasomotor symptoms affect up to 80% of women in perimenopause and can last into the mid-60s or early 70s (U.S. Medicine; ACP guideline).
- First line (strong recommendation): estrogen plus a progestogen if you have a uterus, or estrogen alone if you do not. Second line: desvenlafaxine or venlafaxine. Third line: escitalopram or paroxetine, gabapentin, or elinzanetant or fezolinetant.
The evidence base
What the hot flashes treatment guidelines were based on
A companion systematic review by Diem and colleagues, also in Annals of Internal Medicine, included 90 randomized trials of at least eight weeks, with searches through March 3, 2026. U.S. Medicine reports that evidence certainty was low to moderate for most comparisons, that most trials were short-term, and that long-term harms data are limited. VA clinicians co-authored the work. We read the U.S. Medicine article in full and the guideline only at abstract/snippet level.
Value and limits
Other points in the hot flashes treatment guidelines
U.S. Medicine reports that estrogens with or without a progestogen were judged high economic value, while fezolinetant was judged low value. The panel said clinicians should use informed decision-making and discuss benefits, harms, contraindications, other conditions, preferences, cost and access. It also said more evidence is needed for people who cannot use hormone therapy and for newer nonhormonal agents.
FAQ
Hot flashes treatment guidelines: quick answers
What do the hot flashes treatment guidelines recommend first?
What if hormones are not an option under these hot flashes treatment guidelines?
Do hot flashes treatment guidelines mean I should start a medicine from this page?
Do hot flashes treatment guidelines say an antiperspirant treats hot flashes?
How strong is the evidence behind these hot flashes treatment guidelines?
What the systematic review behind the hot flashes treatment guidelines found
Compared with placebo, the review reported that estrogens with or without progestogens, conjugated estrogen with bazedoxifene, and oxybutynin reduced both frequency and severity of vasomotor symptoms. Neurokinin receptor antagonists, SNRIs, SSRIs, gabapentin and progestogens reduced frequency but not severity, according to the U.S. Medicine summary. Estrogen effect varied by dose but not by route. Estrogens, neurokinin receptor antagonists, SNRIs and SSRIs improved menopause-related quality of life; several non-estrogen options improved sleep quality. Few serious adverse events were reported in the trials, but the studies were not designed to assess long-term harms and observational studies of long-term harms were not included.
Limits of this hot flashes treatment guidelines summary
We read the free U.S. Medicine news article in full. We did not read the complete Annals guideline or the full systematic review. Details, caveats and dosing discussion that appear only in those papers are not included here. This page cannot tell you which option, if any, is right for you.
Hot flashes treatment guidelines do not cover underarm sweating
Vasomotor symptoms are not the same as ordinary underarm sweating. For related Maxim pages, see menopause hot flashes and night sweats guidance and menopause night sweats vs underarm sweating.
Sources
- Mooney B. New Guidelines Endorse Specific Pharmacologic Treatments for Menopausal Vasomotor Symptoms. U.S. Medicine, Nov 12, 2026 (full news article read).
- Qaseem A, Mackey K, Yost J, Shekelle PG, Shamliyan TA, Cross JT Jr; Clinical Guidelines Committee of the American College of Physicians. Pharmacologic Treatments for Females With Menopausal Vasomotor Symptoms: A Clinical Guideline From the American College of Physicians. Ann Intern Med. 2026 Oct 6. doi: 10.7326/ANNALS-26-01205 (PMID 42832802). Abstract/snippet only; full guideline not reviewed.
- Diem S, Landsteiner A, Langsetmo L, et al. Pharmacologic Treatments for Female Menopausal Vasomotor Symptoms: A Systematic Review and Meta-analysis for the American College of Physicians. Ann Intern Med. 2026 Oct 6. doi: 10.7326/ANNALS-26-00943 (PMID 42832800). Findings summarized from the U.S. Medicine report.
Educational information, not a diagnosis or medical advice. Sources were opened and read on Nov 13, 2026. This summary is not evidence for any Maxim product and is not a treatment plan.
Questions about these hot flashes treatment guidelines?
Talk with a clinician who can review your history, risks and preferences. Do not start or stop a medicine based on this page.
The treatment ladderRead the sourcesEducational information only, not medical advice. The guideline did not test Maxim, and Maxim makes no claim to treat hot flashes, night sweats or menopause.